• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12B filed by BioDelivery Sciences International Inc.

    4/1/22 5:02:37 PM ET
    $BDSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BDSI alert in real time by email
    15-12B 1 tm2211058d1_1512b.htm 15-12B

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 15

     

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

     

    Commission File Number: 001-31361

     

     

     

    BIODELIVERY SCIENCES INTERNATIONAL, INC.

    (BIODELIVERY SCIENCES INTERNATIONAL, INC., AS SUCCESSOR BY MERGER WITH BRISTOL ACQUISITION COMPANY INC.)

    (Exact name of registrant as specified in its charter)

     

     

     

    4121 ParkLake Avenue, Suite 225

    Raleigh, NC 27612

    (919) 582-9050 

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Common stock, par value $0.001 per share

    (Title of each class of securities covered by this Form)

     

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)   x
    Rule 12g-4(a)(2)   ¨
    Rule 12h-3(b)(1)(i)   x
    Rule 12h-3(b)(1)(ii)   ¨
    Rule 15d-6   ¨
    Rule 15d-22(b)   ¨

     

    Approximate number of holders of record as of the certification or notice date: One (1)

     

     

     

     

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, BioDelivery Sciences International, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Date: April 1, 2022

     

      BIODELIVERY SCIENCES INTERNATIONAL, INC.,
    (as successor by merger with Bristol Acquisition Company Inc.)  
         
      By: /s/ Joseph Ciaffoni  
        Joseph Ciaffoni
    President and Chief Executive Officer

     

     

     

    Get the next $BDSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BDSI

    DatePrice TargetRatingAnalyst
    2/15/2022$5.00 → $5.60Overweight → Neutral
    Piper Sandler
    1/21/2022$4.00 → $4.50Neutral
    HC Wainwright & Co.
    11/4/2021$6.00 → $4.50Buy → Neutral
    HC Wainwright & Co.
    8/5/2021$5.50 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings